Search Result

Results for "

SV

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Synaptic Vesicle Proteins (4) Amyloid-β (1) Antibiotic (4) Apoptosis (1) Autophagy (8) Bacterial (4) Bcl-2 Family (1) DNA Methyltransferase (4) DNA/RNA Synthesis (7) Dopamine Receptor (2) Drug Metabolite (3) EBV (1) Endogenous Metabolite (1) ERK (1) Ferroptosis (2) Fungal (1) GABA Receptor (1) GLP Receptor (2) HIV (3) HMG-CoA Reductase (HMGCR) (8) HPV (1) HSP (1) Isotope-Labeled Compounds (2) Liposome (3) MDM-2/p53 (1) Radionuclide-Drug Conjugates (RDCs) (1) Small Interfering RNA (siRNA) (4) TNF Receptor (1) Topoisomerase (1) Virus Protease (1)
By Research Areas:	Cancer (19) Cardiovascular Disease (2) Infection (14) Inflammation/Immunology (14) Metabolic Disease (11) Neurological Disease (13)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (3) siRNAs (4)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: Synaptic Vesicle Proteins

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-143312E

(S)-V-0219 hydrochloride	GLP Receptor	Metabolic Disease
(S)-V-0219 hydrochloride is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (S)-V-0219 hydrochloride activates calcium fluxes in HEK cells stably expressing hGLP-1R. (S)-V-0219 hydrochloride is orally active and ameliorates high glucose levels in mice and inhibits feeding behavior in fasted mice .

HY-111241

SV 293	Dopamine Receptor	Neurological Disease
SV 293 is a selective antagonist with neutral antagonist activity. SV 293 binds to human D2 receptors with 100-fold higher affinity and has lower affinity for human D3 and D4 dopamine receptor subtypes. SV 293 was found to block the effects of the full agonist quinpirole in forskolin-dependent adenylate acylase inhibition assays and electrophysiological assays. SV 293 can be used as a useful pharmacological tool to study the role of dopamine D2-like receptor subtypes in dopamine pathways associated with neurological, neuropsychiatric and movement disorders .

HY-111242

SV 156	Dopamine Receptor	Neurological Disease
SV 156 is a potent and selective D2 dopamine receptor antagonist, with a K_i of 2.5 nM for hD2. SV 156 has approximately 40-fold binding selectivity for D2 dopamine receptors compared to the D3 receptor subtype. SV 156 can be used for L-DOPA (HY-N0304)-associated abnormal involuntary movements (AIMs) research .

HY-147547

SV5	Amyloid-β	Neurological Disease
SV5 is a potent anti-Alzheimer agent. SV5 can significantly protect SHSY-5Y cells against Aβ_1-42-induced death. SV5 shows moderate antioxidant and good neuroprotective activities. SV5 shows the high stability in human plasma and the best pharmacological profile .

HY-RS16880

Sv2a Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)
Sv2a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sv2a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sv2a Mouse Pre-designed siRNA Set A Sv2a Mouse Pre-designed siRNA Set A

HY-RS14054

SV2A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
SV2A Human Pre-designed siRNA Set A contains three designed siRNAs for SV2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SV2A Human Pre-designed siRNA Set A SV2A Human Pre-designed siRNA Set A

HY-RS14056

SV2C Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
SV2C Human Pre-designed siRNA Set A contains three designed siRNAs for SV2C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SV2C Human Pre-designed siRNA Set A SV2C Human Pre-designed siRNA Set A

HY-RS14055

SV2B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
SV2B Human Pre-designed siRNA Set A contains three designed siRNAs for SV2B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SV2B Human Pre-designed siRNA Set A SV2B Human Pre-designed siRNA Set A

HY-143312C

(S)-V-0219	GLP Receptor	Metabolic Disease
(S)-V-0219 is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (S)-V-0219 activates calcium fluxes in HEK cells stably expressing hGLP-1R. (S)-V-0219 is orally active and ameliorates high glucose levels in mice and inhibits feeding behavior in fasted mice .

HY-B1907A

Rifamycin Rifamycin SV	Antibiotic Bacterial DNA/RNA Synthesis	Infection Inflammation/Immunology
Rifamycin (Rifamycin SV) is an orally active ansamycin antibiotic. Rifamycin inhibits DNA-dependent RNA synthesis. Rifamycin has antibacterial activity against Mycobacterium tuberculosis. Rifamycin interferes with hepatic bile acid metabolism. Rifamycin has anti-inflammatory effects. Rifamycin can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation .

HY-B1907

Rifamycin sodium Rifamycin SV sodium	Antibiotic Bacterial DNA/RNA Synthesis	Infection Inflammation/Immunology
Rifamycin sodium (Rifamycin SV monosodium) is an orally active ansamycin antibiotic. Rifamycin sodium inhibits DNA-dependent RNA synthesis. Rifamycin sodium has antibacterial activity against Mycobacterium tuberculosis. Rifamycin sodium interferes with hepatic bile acid metabolism. Rifamycin sodium has anti-inflammatory effects. Rifamycin sodium can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation .

HY-B1907R

Rifamycin (sodium) (Standard) Rifamycin SV (sodium) (Standard)	Bacterial Antibiotic	Infection
Rifamycin (sodium) (Standard) is the analytical standard of Rifamycin (sodium). This product is intended for research and analytical applications. Rifamycin sodium (Rifamycin SV sodium) is an orally active ansamycin antibiotic. Rifamycin sodium inhibits DNA-dependent RNA synthesis. Rifamycin sodium has antibacterial activity against Mycobacterium tuberculosis. Rifamycin sodium interferes with hepatic bile acid metabolism. Rifamycin sodium has anti-inflammatory effects. Rifamycin sodium can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation .

HY-P10828

MAPI	Virus Protease	Infection Inflammation/Immunology
MAPI is a polypeptide irreversible 3C cysteine protease (SV3CP) inhibitor. MAPI inhibits SV3CP by covalently binding its C-terminal Michael-acceptor extension to the active site thiol of SV3CP Cys 139. MAPI is promising for research of noroviruses infection .

HY-119810

Seletracetam Ucb 44212	Synaptic Vesicle Proteins	Neurological Disease
Seletracetam (Ucb 44212), as an analog of the antiepileptic agent Levetiracetam, is a *SV2A* modulator for the research of epilepsy .

HY-157999

SDI-118	Synaptic Vesicle Proteins	Neurological Disease
SDI-118 is an orally active modulator for synaptic vesicle glycoprotein 2A (SV2A) with an IC₅₀ of 13 nM .

HY-119810A

Seletracetam lithium Ucb 44212 lithium	HIV	Neurological Disease
Seletracetam (Ucb 44212) lithium, as an analog of the antiepileptic agent Levetiracetam, is a *SV2A* modulator for the research of epilepsy .

HY-136873

UCB-J	Synaptic Vesicle Proteins	Others
UCB-J is a positron emission tomography (PET) radioligand for the synaptic vesicle protein 2A (SV2A) .

HY-119810B

Seletracetam lithium bromide Ucb 44212 lithium bromide	Synaptic Vesicle Proteins	Neurological Disease
Seletracetam (Ucb 44212) lithium bromide, an analog of the antiepileptic agent Levetiracetam, is a *SV2A* modulator for the research of epilepsy .

HY-15865

FR901463	DNA/RNA Synthesis	Cancer
FR901463 is a potent anti-cancer agent and can be used for cancer research. FR901463 enhances the transcriptional activity of the promoter of SV40 DNA virus .

HY-114646

TMC-205	Endogenous Metabolite	Cancer
TMC-205 is a natural fungal metabolite with antiproliferative activity against cancer cell lines. TMC-205 is a transcriptional up-regulator of SV40 promoter .

HY-13234S

Rifaximin-d6	Isotope-Labeled Compounds Bacterial Antibiotic	Infection
Rifaximin-d₆ is the deuterium labeled Rifaximin. Rifaximin is an orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity[1][2].

HY-167830

SDM-8	Radionuclide-Drug Conjugates (RDCs)	Neurological Disease
SDM-8 is a difluoro-analog of UCB-J (HY-136873).SDM-8 shows high *SV2A* binding affinity with a K_i of 0.58 nM. SDM-8 can be used in the study of Alzheimer's disease .

HY-B0589

Atorvastatin Maximum Cited Publications 44 Publications Verification	HMG-CoA Reductase (HMGCR) Autophagy	Metabolic Disease Inflammation/Immunology Cancer
Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively .

HY-B0106

Levetiracetam 1 Publications Verification UCB L059	DNA Methyltransferase	Neurological Disease Cancer
Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein *SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT*, thus increasing Temozolomide effectiveness. A chemosensitizer agent .

HY-108257

Atorvastatin sodium	HMG-CoA Reductase (HMGCR) Autophagy	Metabolic Disease Inflammation/Immunology
Atorvastatin sodium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin sodium inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively .

HY-B0589E

Atorvastatin hemicalcium trihydrate Maximum Cited Publications 44 Publications Verification	HMG-CoA Reductase (HMGCR) Autophagy	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Atorvastatin hemicalcium trihydrate is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium trihydrate inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively .

HY-P1566

MPG, HIV related	HIV	Infection
MPG, HIV related is 27-aa peptide, derived from both the nuclear localisation sequence of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41 and is a potent delivery agent for the generalised delivery of nucleic acids and of oligonucleotides into cultured cells.

HY-135151

Difluoro atorvastatin Fluoroatorvastatin	Drug Metabolite	Cardiovascular Disease
Difluoro atorvastatin (Fluoroatorvastatin) is an impurity of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively .

HY-N11698

Bakuchicin Allopsoralen	Topoisomerase	Infection
Bakuchicin (Allopsoralen) is a compound that can be found in Psoralea corylifolia. It has certain inhibitory activity against topoisomerase II. In the cell model infected with Simian virus 40 (SV40), the IC₅₀ of Bakuchicin against topoisomerase II is 404 μM. Bakuchicin can be used in the research of the anti-infection field .

HY-P1876

NLS (PKKKRKV)	DNA/RNA Synthesis	Cancer
NLS (PKKKRKV) is a nuclear localization signal (NLS) derived from the simian virus 40 large tumor antigen (SV40 large T antigen), that mediates binding of the karyophilic protein to importin α. NLS (PKKKRKV) can function as a method to enhance nuclear entry in the field of gene transfer research .

HY-119098

GSK983	EBV HPV	Infection
GSK983 is a broad-spectrum antiviral agent. GSK983 inhibits the replication of adenovirus-5 (Ad-5) and polyoma virus SV40. GSK983 inhibits the growth of cell lines immortalized by EBV, HTLV1, HPV. GSK983 induces the expression of interferon-stimulated genes .

HY-124429

FQI1	ERK	Cancer
FQI1 is a Late SV40 Factor (LSF) inhibitor. FQI1 inhibits cell proliferation, with IC₅₀s of 3, 0.79, 6.3 μM for NIH/3T3, HeLa, A549 cells. FQI1 can be used for cancer research .

HY-B0106S

Levetiracetam-d6 UCB L059-d₆	Isotope-Labeled Compounds DNA Methyltransferase	Neurological Disease Cancer
Levetiracetam-d₆ is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent[1][2].

HY-B0106S1

Levetiracetam-d3 UCB L059-d₃	DNA Methyltransferase	Neurological Disease Cancer
Levetiracetam-d₃ is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent[1][2].

HY-B0589S1

Atorvastatin-d5 sodium	HMG-CoA Reductase (HMGCR) Autophagy	Metabolic Disease Inflammation/Immunology
Atorvastatin-d₅ (sodium) is the deuterium labeled Atorvastatin sodium. Atorvastatin sodium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin sodium inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3][4].

HY-B0106R

Levetiracetam (Standard)	DNA Methyltransferase	Neurological Disease Cancer
Levetiracetam (Standard) is the analytical standard of Levetiracetam. This product is intended for research and analytical applications. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .

HY-B0589S

Atorvastatin-d5 hemicalcium	HMG-CoA Reductase (HMGCR) Autophagy	Metabolic Disease Inflammation/Immunology
Atorvastatin-d₅ (hemicalcium) is the deuterium labeled Atorvastatin. Atorvastatin hemicalcium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3].

HY-12772R

Hydroxy Itraconazole (Standard)	Fungal Drug Metabolite	Others
Levetiracetam (Standard) is the analytical standard of Levetiracetam. This product is intended for research and analytical applications. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .

HY-135374

(3R,5S)-Atorvastatin sodium	Drug Metabolite	Metabolic Disease Inflammation/Immunology
(3R,5S)-Atorvastatin sodium is an impurity of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively .

HY-B0589R

Atorvastatin (Standard)	HMG-CoA Reductase (HMGCR) Autophagy	Metabolic Disease Inflammation/Immunology Cancer
Atorvastatin (Standard) is the analytical standard of Atorvastatin. This product is intended for research and analytical applications. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively .

HY-17379

Atorvastatin hemicalcium salt Maximum Cited Publications 44 Publications Verification CI-981; Atorvastatin hemicalcium	HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis	Metabolic Disease Inflammation/Immunology Cancer
Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively .

HY-172714

DSPE-PEG2000-MPG	Liposome	Infection
DSPE-PEG2000-MPG is a PEG compound which composed of DSPE and a peptide vector (MPG). MPG is derived from both the nuclear localisation sequence (NLS) of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41. MPG could deliver short oligonucleotides into cells efficiently and independently of the endosomal pathway .

HY-172713

DSPE-PEG1000-MPG	Liposome	Infection
DSPE-PEG1000-MPG is a PEG compound which composed of DSPE and a peptide vector (MPG). MPG is derived from both the nuclear localisation sequence (NLS) of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41. MPG could deliver short oligonucleotides into cells efficiently and independently of the endosomal pathway .

HY-P990006

Duvakitug TEV-48574	TNF Receptor	Inflammation/Immunology
Duvakitug (TEV-48574) is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) .

HY-172715

DSPE-PEG5000-MPG	Liposome	Infection
DSPE-PEG5000-MPG is a PEG compound which composed of DSPE and a peptide vector (MPG). MPG is derived from both the nuclear localisation sequence (NLS) of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41. MPG could deliver short oligonucleotides into cells efficiently and independently of the endosomal pathway .

HY-109009

Padsevonil 1 Publications Verification UCB-0942	GABA Receptor	Neurological Disease
Padsevonil (UCB0942) is a potent antiepileptic agent that selectively acts on presynaptic and postsynaptic targets. Padsevonil binds to synaptic vesicular protein 2 (SV2) with high affinity. Padsevonil is also a positive allosteric modulator and partial agonist of GABA_AR, with high potency against α1 and α5 receptors. Padsevonil has antiepileptic effects in a variety of rodent models .

HY-P1876B

NLS (PKKKRKV) hydrochloride 1 Publications Verification	DNA/RNA Synthesis	Cancer
NLS (PKKKRKV) hydrochloride is the hydrochloride form of NLS (PKKKRKV) (HY-P1876). NLS (PKKKRKV) is a nuclear localization signal (NLS) derived from the simian virus 40 large tumor antigen (SV40 large T antigen), that mediates binding of the karyophilic protein to importin α. NLS (PKKKRKV) can function as a method to enhance nuclear entry in the field of gene transfer research .

HY-116683

116-9e MAL2-11B	HSP DNA/RNA Synthesis	Infection Cancer
116-9e (MAL2-11B) is a Hsp70 co-chaperone DNAJA1 inhibitor. 116-9e inhibits Simian Virus 40 (SV40) replication and DNA synthesis. 116-9e inhibits tumor antigen (TAg)’s endogenous ATPase activity and the TAg-mediated activation of Hsp70 .

HY-P1876A

NLS (PKKKRKV) TFA	DNA/RNA Synthesis	Cancer
NLS (PKKKRKV) TFA is the TFA form of NLS (PKKKRKV) (HY-P1876). NLS (PKKKRKV) is a nuclear localization signal (NLS) derived from the simian virus 40 large tumor antigen (SV40 large T antigen), that mediates binding of the karyophilic protein to importin α. NLS (PKKKRKV) can function as a method to enhance nuclear entry in the field of gene transfer research .

HY-17379R

Atorvastatin (hemicalcium salt) (Standard) CI-981 (Standard); Atorvastatin hemicalcium (Standard)	HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis	Metabolic Disease Inflammation/Immunology Cancer
Atorvastatin (hemicalcium salt) (Standard) is the analytical standard of Atorvastatin (hemicalcium salt). This product is intended for research and analytical applications. Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively .

Cat. No.	Product Name	Type

HY-172714

DSPE-PEG2000-MPG	Drug Delivery
DSPE-PEG2000-MPG is a PEG compound which composed of DSPE and a peptide vector (MPG). MPG is derived from both the nuclear localisation sequence (NLS) of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41. MPG could deliver short oligonucleotides into cells efficiently and independently of the endosomal pathway .

HY-172713

DSPE-PEG1000-MPG	Drug Delivery
DSPE-PEG1000-MPG is a PEG compound which composed of DSPE and a peptide vector (MPG). MPG is derived from both the nuclear localisation sequence (NLS) of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41. MPG could deliver short oligonucleotides into cells efficiently and independently of the endosomal pathway .

HY-172715

DSPE-PEG5000-MPG	Drug Delivery
DSPE-PEG5000-MPG is a PEG compound which composed of DSPE and a peptide vector (MPG). MPG is derived from both the nuclear localisation sequence (NLS) of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41. MPG could deliver short oligonucleotides into cells efficiently and independently of the endosomal pathway .

Cat. No.	Product Name	Target	Research Area

HY-P0310

SV40 large T antigen NLS	Peptides	Infection
SV40 large T antigen NLS is from Large T antigen residue 47 to 55, enables protein import into cell nucleus.

HY-P1877A

SV40 T-Ag-derived NLS peptide TFA	Peptides	Cancer
SV40 T-Ag-derived NLS peptide TFA is a nuclear localization signal DNA tagged to this peptide efficiently translocates into the cell nucleus .

HY-P3827

Cys-Gly-Tyr-Gly-Pro-Lys-Lys-Lys-Arg-Lys-Val-Gly-Gly	Peptides	Inflammation/Immunology
Cys-Gly-Tyr-Gly-Pro-Lys-Lys-Lys-Arg-Lys-Val-Gly-Gly is a13-mer synthetic peptide containing seven amino acids homologous to SV40 T antigen. Cys-Gly-Tyr-Gly-Pro-Lys-Lys-Lys-Arg-Lys-Val-Gly-Gly is capable of inducing nuclear transport .